IQVIA Holdings Inc. (IQV) saw its stock soar 6.16% in pre-market trading on Thursday, following the company's better-than-expected fourth-quarter earnings and revenue results, driven by robust demand for its healthcare data and analytics services.

For the fourth quarter of 2024, IQVIA reported adjusted earnings per share of $3.12, narrowly beating Wall Street's consensus estimate of $3.11. The company's revenue came in at $3.96 billion, surpassing analysts' expectations of $3.94 billion.

The strong performance was fueled by IQVIA's Technology & Analytics Solutions segment, which provides advanced data insights and technology services to pharmaceutical and consumer healthcare companies. This segment's revenue reached $1.66 billion, exceeding estimates of $1.63 billion, as clients increased spending to leverage IQVIA's analytical capabilities.

However, the company's Research & Development Solutions unit faced some headwinds, including cancellations from large drugmakers reprioritizing their development pipelines. Despite these challenges, the unit's book-to-bill ratio, which measures the number of orders received compared to those fulfilled, came in at a better-than-expected 1.20x.

Looking ahead, IQVIA reaffirmed its full-year 2025 adjusted earnings per share guidance range of $11.70 to $12.10, with the midpoint in line with analysts' estimates of around $11.90. The company's revenue guidance range of $15.73 billion to $16.13 billion was slightly below Wall Street's expectations, with the midpoint of $15.93 billion implying a 3.4% year-over-year growth.